Global Medical Hub
- The enthusiasm and dedication of CHA medical educators and practitioners keeps CHA University at the forefront of worldwide trends in medical education and research.
CHA University sets out a new paradigm for medical
education and research, and leads the trends in the health care industry.
- CHA University operates the treatment center for reproductive medicine in conjunction with Columbia University in the City of New York; as well as the CHA Regenerative Medicine Institute in Los Angeles, California; and the Medical Information Center in Tokyo, Japan. Also with the CHA Stem Cell Institute, the CHA Basic Medicine Institute, CHA Institute of Clinical Medicine, and with CHA Cellular Gene Therapy Institute, CHA University is setting the trends in world medicare and is establishing the mainstream stem cell and reproductive medicine cluster around the globe.
- CHA claims many firsts in medicine First in the world, first in the East, and first in Korea.
- CHA University has received the prestigious Best Paper Awards in the infertility and reproductive medicine six times to date, and the breakthroughs CHA has achieved claim many firsts in medical technology--CHA is credited for coming up with the new kind of ovum freezing method, utilizing the slush nitrogen for the first time in the world; and also for creating the map for 31 different types of human embryonic stem cell. CHA University has developed the cervical cancer test kit for the first time in the industry; and a woman successfully became pregnant from an immature ovus through in vitro fertilization for the first time in history at a CHA research facility.
- The researchers from CHA Stem Cell Institute accomplishe a world first in the development of stem cell therapy.
- CHA Stem Cell Institute
- A team of researchers at CHA Stem Cell Institute has come up with a blood cell therapy method using human embryonic stem cells for the first time in the world. This discovery was published in Circulation, a highly reputable name in clinical publication, ascertaining Korea's status as one of the leading countries in the field.
- CHA introduces a new ovum-freezing method using the slush nitrogen.
Dr. Cha Kwang Yul, the President and the Dean at CHA University, is also called
the Dean of reproductive medicine. By improving the existing ovum freezing method,
Drs. Cha Kwang Yul and Yoon Tae-ghi utilized the slush nitrogen to freeze the egg
in a more efficient manner--with this new method the eggs were less prone to damage,
thus increasing the chance for pregancy.
Infertility is an important, often overlooked, complication of cancer treatment. Chemotherapy and radiation can both impact a person's ability to have a child. Ovum freezing method is an excellent fertility-preserving options for those who had to go through aforementioned cancer and post-cancer treatments, or for those who oppose the idea of cryopreservation of human embryos, for moral or religious reason.
- CHA successfully cures adult leukemia with stem cell transplantion for the first time in Korea
- The hematopoietic stem cell transplantation center
- August 2005. CHA Medical Center has succeeded for the first time in korea in the transplantion of the cord blood stem cells to cure a leukemia patient thanks to CHA's unique stem cell extraction technology and the know-how in this subject. The group currently owns and operates the largest stem cell treatment facilities in the nation, and the hematopoietic stem cell transplantation center within the Bundang Cha Medical Center.
- The Korean government designates CHA as the partner in the development of DNA Chip technology.
- The Dielectric Reproductive Medicine Research Lab
- The gestational toxicosis prediction DNA chip and the pregnancy diagnostic DNA chip are being developed by CHA as a government project. Once these chips are completed, the diagnosis for all hereditary disorders legally permitted today can be performed within just two days, and this new technology is expected to dominate the pregnancy diagnosis and the dereditary disorder diagnosis markets, which amount to 300 million dollars in market size.
- CHA discovers tumor suppressor genes for the first time in world medical history.
- For the first time in the world, a team of researchers at CHA University, led by Professor Baek Gwang Hyun, has discovered the enzyme which plays a crucial role in the suppression of the growth of cancer cells. The newly discovered mHOUSP enzyme is known to control the tumor suppressing p53 protein.
- CHA successfully produces sperm cells from the
reproductive stem cells from testicular tissue.
- At the 2003 Society for Male Reproduction and Urology annual meeting in San Antonio, Texas, the best clinical paper award went to a group of researchers from CHA Fertility Center, on the study of "Differentiation induction of mouse testicular spermatids through the separation, proliferation, and in-vitro culturing of the reproductive stem cells from mouse testis." suggesting a possible approach to treating male infertility.
- The Bundang CHA Medical Center creates and markets world's first cervical cancer test kit.
- The kit is capable of testing at pre-childbirth for all gene types which can cause cervical cancer.
- The Kim Seung-jo and Lee Sang-hwa team at Bundang CHA Medical Center has developed Albioamp-p I, world's first cervical cancer test kit and commercialized it. The test kit is capable of identifying all thirty types of papilloma virogenes that are known to be the cause of cervical cancer.
- CHA Fertility Center reveals the genes responsible for recurrent miscarriage.
- Drs. Lee Sook-hwan and Baek Gwang-hyun at CHA Fertility Center has revealed the genes responsible for recurrent miscarriage, paving the way for further treatment of habitual miscarriage. This study was published on the Reproduction, Fertility, and Development Journal; as well as on the American and the European societies of reproductive medicine publications.
- CHA Cell and Gene Therapy Institute divides and differentiates a stem cell into brain cells for the first time in Korea; and registers two types of embryonic stem cell to U.S. National Institutes of Health.
- A team of researchers at CHA Cell and Gene Therapy Institute, led by Director Hyung-min Jung, has transplanted the mouse embryonic stem cells into the brain of a mouse, successfully restoring the damaged brain cells to function. The Institute is also in the middle of a research to create dopamine nerve cells from human embryonic stem cells, and when completed, the study will be used to treat diseases that are incurable today, such as Parkinson's syndrome and Huntington disease.
- CHA Fertility Center develops a unique method of ova freezing through vitrification.
- The vitrification ovum-freezing method involves freezing the embryo about 600 times faster than ever before. This ultrarapid process is so fast that it literally allows no time for intracellular ice to form. This breakthrough method of cryopreservation of human embryos was introduced by the researchers at CHA Fertility Center, and is a patented, CHA-proprietary ovum freezing technology. The discovery was recognized and awarded by both American Society for Reproductive Medicine and the International Federation of Fertility Societies in 1998.
- CHA Fertility Center achieves pregnancy through in vitro fertilization of immature ova.
- In 1998, CHA Fertility Center has successfully achieved pregnancy through in-vitro fertilization of immature ova for the first time in human history, another breakthrough for CHA experts. Pioneered by CHA, this method is now used by infertility clinics all over the world, and can be effective for women who went through early menopause or are provided with someone else's immature ova. Women about to undergo cancer treatment can store their immature eggs for cryopreservation, and use them after the anti-cancer treatment has been completed.